CSIMarket
 


Alx Oncology Holdings Inc  (ALXO)
Other Ticker:  
 
 

ALXO's Net Income Growth by Quarter and Year

Alx Oncology Holdings Inc's Net Income results by quarter and year




ALXO Net Income (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -30.71 -28.44 21.51
III Quarter September -50.99 -35.32 -24.57 -10.18
II Quarter June -34.16 -32.92 -16.27 -11.33
I Quarter March -30.18 -24.53 -14.19 0.00
FY   -115.33 -123.48 -83.47 0.00



ALXO Net Income third quarter 2023 Y/Y Growth Comment
Alx Oncology Holdings Inc in the third quarter 2023 recorded net loss of $ -50.99 millions.

According to the results reported in the third quarter 2023, Alx Oncology Holdings Inc achieved the best Net Income growth in Major Pharmaceutical Preparations industry. While Alx Oncology Holdings Inc' s Net Income no change of % ranks overall at the positon no. in the third quarter 2023.




ALXO Net Income ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Alx Oncology Holdings Inc's third quarter 2023 Net Income $ -50.99 millions ALXO's Income Statement
Alx Oncology Holdings Inc's third quarter 2022 Net Income $ -35.32 millions Quarterly ALXO's Income Statement
New: More ALXO's historic Net Income Growth >>


ALXO Net Income (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Net Income third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Income third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Alx Oncology Holdings Inc's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ALXO's III. Quarter Q/Q Net Income Comment
Current net loss of -50.99 millions by Alx Oncology Holdings Inc look even more unfavourable if you take a look at -34.16 millions in the previous quarter.

Within Major Pharmaceutical Preparations industry Alx Oncology Holdings Inc achieved highest sequential Net Income growth. While Alx Oncology Holdings Inc's Net Income growth quarter on quarter, overall rank is .


Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ALXO's III. Quarter Q/Q Net Income Comment
III. Quarter 2023 net loss of -50.99 millions by Alx Oncology Holdings Inc look even more unfavourable if you take a look at -34.16 millions net loss in the previous quarter.

Within Major Pharmaceutical Preparations industry Alx Oncology Holdings Inc achieved highest sequential Net Income growth. While Alx Oncology Holdings Inc's Net Income growth quarter on quarter, overall rank is .


Alx Oncology Holdings Inc's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Net Income 12 Months Ending $ -146.04 $ -130.37 $ -129.13 $ -123.48 $ -121.21
Y / Y Net Income Growth (TTM) - - - - -
Year on Year Net Income Growth Overall Ranking # # # # #
Seqeuential Net Income Change (TTM) - - - - -
Seq. Net Income Growth (TTM) Overall Ranking # # # # #




Cumulative Net Income growth Comment
Alx Oncology Holdings Inc' has realized cumulative trailing twelve months net loss of $ -146 millions in the Sep 30 2023 period.
The business is worsening as the cumulative net loss is becoming larger from $ -130.37 millions for the period from Jun 30 2023 to Sep 30 2022 and $ -110.457 millions for the twelve months ending in the quarter a year ago Lily C. Jackson wrote.

Alx Oncology Holdings Inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Net Income growth Comment
Alx Oncology Holdings Inc' has realized cumulative trailing twelve months net loss of $ -146 millions in the Sep 30 2023 period.
The situation is worsening as the cumulative net loss is inflating from $ -130.37 millions in TTM ending quarter Jun 30 2023 and $ -110.457 millions for the twelve months ending in the quarter Sep 30 2022 Lily C. Jackson wrote.

Alx Oncology Holdings Inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Net Income Growth
Major Pharmaceutical Preparations Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
ALXO's Net Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for ALXO's Competitors
Net Income Growth for Alx Oncology Holdings Inc's Suppliers
Net Income Growth for ALXO's Customers

You may also want to know
ALXO's Annual Growth Rates ALXO's Profitability Ratios ALXO's Asset Turnover Ratio ALXO's Dividend Growth
ALXO's Roe ALXO's Valuation Ratios ALXO's Financial Strength Ratios ALXO's Dividend Payout Ratio
ALXO's Roa ALXO's Inventory Turnover Ratio ALXO's Growth Rates ALXO's Dividend Comparisons



Companies with similar Net Income no change for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Net Income for the quarter ending Sep 30 2023
Integer Holdings Corporation69.75%$ 69.752 millions
Encompass Health Corporation69.25%$ 69.254 millions
Merit Medical Systems Inc69.16%$ 69.159 millions
Align Technology inc 67.02%$ 67.025 millions
Select Medical Holdings Corp59.51%$ 59.513 millions
Infusystem Holdings Inc55.53%$ 55.530 millions
Incyte Corporation51.87%$ 51.868 millions
Teva Pharmaceutical Industries Limited51.72%$ 51.724 millions
Semler Scientific Inc 50.04%$ 50.041 millions
Iradimed Corporation47.86%$ 47.856 millions
Merck and Co Inc 46.02%$ 46.019 millions
Lftd Partners Inc 45.85%$ 45.849 millions
Msa Safety Incorporated45.32%$ 45.317 millions
Option Care Health Inc 45.02%$ 45.022 millions
Ir med Inc 37.73%$ 37.734 millions
Lemaitre Vascular Inc 37.50%$ 37.500 millions
West Pharmaceutical Services Inc 33.75%$ 33.748 millions
Addus Homecare Corporation33.51%$ 33.509 millions
Halozyme Therapeutics Inc 32.78%$ 32.779 millions
Chemed Corporation31.80%$ 31.799 millions
Intuitive Surgical Inc 29.29%$ 29.289 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com